12,625 Shares in Abbott Laboratories (NYSE:ABT) Purchased by Three Seasons Wealth LLC

Three Seasons Wealth LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,625 shares of the healthcare product maker's stock, valued at approximately $1,428,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Kovitz Investment Group Partners LLC lifted its holdings in shares of Abbott Laboratories by 287.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 970,705 shares of the healthcare product maker's stock worth $109,797,000 after acquiring an additional 720,451 shares during the period. Topsail Wealth Management LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $357,000. Empire Financial Management Company LLC lifted its holdings in Abbott Laboratories by 1.4% during the 4th quarter. Empire Financial Management Company LLC now owns 39,326 shares of the healthcare product maker's stock valued at $4,448,000 after purchasing an additional 533 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Abbott Laboratories by 3.7% during the 4th quarter. Integrated Wealth Concepts LLC now owns 36,987 shares of the healthcare product maker's stock valued at $4,184,000 after purchasing an additional 1,330 shares during the last quarter. Finally, Burling Wealth Partners LLC bought a new position in Abbott Laboratories during the 4th quarter valued at about $9,554,000. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, SVP Eric Shroff sold 562 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the transaction, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares of the company's stock, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 116,449 shares of company stock valued at $15,463,316. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 0.4 %

NYSE ABT traded down $0.56 during trading on Wednesday, reaching $129.94. 2,966,021 shares of the stock traded hands, compared to its average volume of 6,056,189. The firm has a market cap of $225.36 billion, a price-to-earnings ratio of 16.99, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80. The stock's 50-day moving average price is $130.44 and its 200 day moving average price is $122.65. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories's payout ratio is currently 30.61%.

Analyst Upgrades and Downgrades

ABT has been the subject of several analyst reports. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Raymond James raised their price objective on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, April 17th. Royal Bank of Canada raised their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Thursday, April 17th. Morgan Stanley raised their price objective on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research report on Thursday, April 17th. Finally, Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $142.59.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.